China Resources Double-Crane PharmaceuticalLtd Future Growth
Future criteria checks 1/6
China Resources Double-Crane PharmaceuticalLtd is forecast to grow earnings and revenue by 16.6% and 8.9% per annum respectively. EPS is expected to grow by 16.3% per annum. Return on equity is forecast to be 13% in 3 years.
Key information
16.6%
Earnings growth rate
16.3%
EPS growth rate
Pharmaceuticals earnings growth | 18.9% |
Revenue growth rate | 8.9% |
Future return on equity | 13.0% |
Analyst coverage | Low |
Last updated | 11 Nov 2024 |
Recent future growth updates
The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Oct 29China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 24Recent updates
The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Oct 29China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Low P/E No Reason For Excitement
Oct 21An Intrinsic Calculation For China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Suggests It's 49% Undervalued
Sep 30We Think China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt With Ease
Jul 16China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 24Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel
Mar 02Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 12,940 | 2,110 | N/A | 2,565 | 2 |
12/31/2025 | 12,888 | 1,910 | N/A | 2,313 | 3 |
12/31/2024 | 11,903 | 1,734 | N/A | 1,892 | 3 |
9/30/2024 | 10,322 | 1,348 | 1,082 | 1,840 | N/A |
6/30/2024 | 10,308 | 1,395 | 1,207 | 1,801 | N/A |
3/31/2024 | 10,285 | 1,374 | 1,201 | 1,812 | N/A |
12/31/2023 | 10,222 | 1,333 | 1,026 | 1,631 | N/A |
9/30/2023 | 10,916 | 1,584 | 1,296 | 1,811 | N/A |
6/30/2023 | 10,558 | 1,428 | 1,028 | 1,514 | N/A |
3/31/2023 | 9,880 | 1,223 | 888 | 1,357 | N/A |
12/31/2022 | 9,625 | 1,180 | 890 | 1,416 | N/A |
9/30/2022 | 9,394 | 1,025 | 611 | 1,258 | N/A |
6/30/2022 | 9,392 | 1,078 | 720 | 1,337 | N/A |
3/31/2022 | 9,222 | 981 | 618 | 1,198 | N/A |
12/31/2021 | 9,112 | 936 | 849 | 1,341 | N/A |
9/30/2021 | 9,006 | 1,021 | 904 | 1,269 | N/A |
6/30/2021 | 8,987 | 1,046 | 964 | 1,328 | N/A |
3/31/2021 | 8,730 | 1,016 | 956 | 1,318 | N/A |
12/31/2020 | 8,504 | 1,005 | 1,012 | 1,360 | N/A |
9/30/2020 | 8,348 | 1,010 | 956 | 1,238 | N/A |
6/30/2020 | 8,663 | 971 | 1,068 | 1,323 | N/A |
3/31/2020 | 8,930 | 1,001 | 1,123 | 1,347 | N/A |
12/31/2019 | 9,381 | 1,055 | 1,198 | 1,440 | N/A |
9/30/2019 | 9,322 | 1,043 | 1,192 | 1,430 | N/A |
6/30/2019 | 9,003 | 1,024 | 1,195 | 1,428 | N/A |
3/31/2019 | 8,720 | 997 | 1,289 | 1,541 | N/A |
12/31/2018 | 8,225 | 969 | 1,240 | 1,469 | N/A |
9/30/2018 | 7,975 | 962 | 1,386 | 1,589 | N/A |
6/30/2018 | 7,434 | 905 | N/A | 1,406 | N/A |
3/31/2018 | 7,032 | 908 | N/A | 1,271 | N/A |
12/31/2017 | 6,422 | 843 | N/A | 1,187 | N/A |
9/30/2017 | 6,103 | 838 | N/A | 1,071 | N/A |
6/30/2017 | 5,725 | 801 | N/A | 1,107 | N/A |
3/31/2017 | 5,584 | 767 | N/A | 911 | N/A |
12/31/2016 | 5,495 | 714 | N/A | 771 | N/A |
9/30/2016 | 5,490 | 705 | N/A | 828 | N/A |
6/30/2016 | 5,414 | 684 | N/A | 775 | N/A |
3/31/2016 | 5,274 | 645 | N/A | 813 | N/A |
12/31/2015 | 5,138 | 661 | N/A | 701 | N/A |
9/30/2015 | 5,733 | 865 | N/A | 1,025 | N/A |
6/30/2015 | 5,562 | 832 | N/A | 1,016 | N/A |
3/31/2015 | 5,413 | 785 | N/A | 876 | N/A |
12/31/2014 | 5,153 | 737 | N/A | 929 | N/A |
9/30/2014 | 4,276 | 776 | N/A | 674 | N/A |
6/30/2014 | 5,184 | 845 | N/A | 539 | N/A |
3/31/2014 | 6,010 | 859 | N/A | 637 | N/A |
12/31/2013 | 6,835 | 871 | N/A | 546 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 600062's forecast earnings growth (16.6% per year) is above the savings rate (2.8%).
Earnings vs Market: 600062's earnings (16.6% per year) are forecast to grow slower than the CN market (25.8% per year).
High Growth Earnings: 600062's earnings are forecast to grow, but not significantly.
Revenue vs Market: 600062's revenue (8.9% per year) is forecast to grow slower than the CN market (13.8% per year).
High Growth Revenue: 600062's revenue (8.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 600062's Return on Equity is forecast to be low in 3 years time (13%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 12:31 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
China Resources Double-Crane Pharmaceutical Co.,Ltd. is covered by 20 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Zhi Xue Diao | Avic Securities Co., Ltd |
Jessica Li | BofA Global Research |
Helena Qiu | CCB International Securities Limited |